Jeremy Berke

Jeremy Berke is a health reporter at The Atlantic, covering the intersection of medicine and public policy. His work focuses on the science and politics of drug policy reform, mental health, and bioethics. Prior to joining The Atlantic in 2021, he was a staff writer at Stat News, where he covered biotechnology and pharmaceuticals. He has also written for The New York Times and Slate.

Biography:  https://www.theatlantic.com/feed/author/jeremy-berke/

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

Biden Administration Announces Plans to Reschedule Cannabis: From Schedule I to III

Biden Administration Announces Plans to Reschedule Cannabis: From Schedule I to III

Broke On: Friday, 03 May 2024 The Biden administration announced plans to loosen federal cannabis restrictions, moving marijuana from schedule I to schedule III on the Controlled Substances Act. This decision follows a review by the Department of Health and Human Services concluding that marijuana has medical benefits and potential for abuse. The change could support Biden among young voters, ease research, and grow the legal cannabis industry projected to reach $70 billion by 2030. However, public comment period and lawsuits are expected.